GSK Reportedly To Lay Off 1,000 In China
This article was originally published in Scrip
After a stormy year in China, GlaxoSmithKline has gone through major changes including the global transfer of its oncology assets to Novartis. But the underlying broader reasons for the company's newly reported layoffs in China could be more deep-rooted and far-reaching.
You may also be interested in...
As the largest manufacturer of active pharmaceutical ingredients globally, China is bracing for more uncertainty amid the global pandemic and fast-changing environment, particularly in the US.
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.